

A review study on the present and novel treatments for metabolic disorder

Omonova Gavhar Sultonovna ¹, Shagufta kalim Khan ¹, Mohammad Faizan ², Muhammad Arsalan Ali Sajid ^{2,*} and Kurbanniyozova Yulduz Allaberganovna ³

¹ Department of pharmacology and clinical pharmacology at Urgench Branch of Tashkent Medical Academy, Urgench, Uzbekistan.

² Faculty of General Medicine, Urgench Branch of Tashkent Medical Academy, Urgench, Uzbekistan.

² Faculty of General Medicine, University of Sargodha, Urgench branch of Tashkent Medical Academy, Uzbekistan, Health Management, IUBH University, Germany.

³ Department of Pharmacology, Urgench Branch of Tashkent Medical Academy, Uzbekistan.

World Journal of Advanced Research and Reviews, 2023, 18(02), 1299–1304

Publication history: Received on 08 April 2023; revised on 18 May 2023; accepted on 21 May 2023

Article DOI: <https://doi.org/10.30574/wjarr.2023.18.2.0911>

Abstract

Metabolic syndrome is the most common issue faced by a large population, especially women and old aged people. This is not only a clinical issue for the women and adults but also a social concern particularly among children and adolescents in high-income areas. The prevention and

Cure are the hottest area of discussion through the years and many recommendations came regarding preventions and treatments as depressing the asprosin hormone level which is a major cause of high appetite and increase sugar level in blood can help in controlling the obesity and few metabolisms, and nutraceuticals discoveries. There are few proposals about adding psychological interventions in treatments, as these people should also be motivated psychologically as these people sometimes these people face social isolation and give up on treatments. In the SARS-COV 2 pandemic the incidences of this syndrome due to restricted movement of people and other factors.

Keywords: Novel treatments; Metabolic Treatments; Asprosin Hormone; Adolescent; Metabolomics

1. Introduction

Metabolic Syndrome, commonly referred to as MetS, is a medical condition characterized by the presence of at least three out of five conditions that include central obesity, hypertension, hyperglycemia, hypertriglyceridemia and low serum high-density lipoprotein. The causes of this syndrome are multifactorial and include factors such as dietary habits, genetic predisposition and lifestyle choices. Studies have shown that over one billion people worldwide suffer from MetS with prevalence on the rise due to urbanization and changes in lifestyle. This is not only a clinical issue but also a social concern particularly among children and adolescents in high-income areas.

The implications of MetS are significant as patients are susceptible to various cardiovascular, cerebral and hepato-renal complications leading to increased all-cause mortality. The presence of MetS also increases the risk of sudden cardiac death with higher adherence to MetS criteria associated with a higher risk of such events. Additionally, this syndrome is associated with systematic adverse outcomes such as glomerular hyperfiltration, nonalcoholic fatty liver disease and excessive mortality.

Recent studies have suggested that adopting a Mediterranean lifestyle including dietary habits, exercise and social interaction may reduce the prevalence of MetS. Furthermore, genetic risk assessment based on four single nucleotide

* Corresponding author: Muhammad Arsalan Ali Sajid

polymorphisms has been proposed to demonstrate the interaction between physical activity and MetS risk in various genetic backgrounds. Several drugs such as metformin, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors have shown promising results in reducing insulin resistance while improving glycemic control thereby reducing cardiovascular risk among patients suffering from MetS.

In conclusion early diagnosis prompt management along with preventive measures are essential for approaching cases related to metabolic syndrome. A Mediterranean lifestyle genetic risk assessment along with pharmacological interventions may provide novel avenues for preventing managing MetS-related complications thereby reducing morbidity and mortality rates associated with this condition.

The COVID-19 pandemic has highlighted metabolic syndrome (MetS) as a potential risk factor for severe complications from viral infections. However, traditional methods for assessing MetS have not taken into account the molecular heterogeneity involved in the disease's progression. In this review, we take a detailed look at recent developments in MetS research, including studies on COVID-19 and MetS, metabolomics and proteomics, and the gut microbiota. We also discuss new therapeutic approaches targeting the molecular diversity of MetS, with the aim of improving individualized precision medicine for metabolic disorders.

2. Metabolic syndrome and sars-CoV-2

Individuals with metabolic syndrome are at risk of ordinary fitness problems, and at some stage in the Covid-19 pandemic, concerns have been raised approximately their improved chance of contamination. In addition to installed hazard factors which includes weight problems, old age, hypertension, and diabetes, the essence of metabolic syndrome changed into located to be connected to covid-19 contamination. A Mexican epidemiological take a look at found that the demise charge was twice as high among individuals who met the standards for metabolic syndrome. Investigations have been conducted to discover the link among weight problems, coronavirus infection, and its demise rate. The angiotensin-converting enzyme 2 receptor and lipid, at the side of intertwined chemokines, were recognized as primary gamers on this association. Adipocytes fantastically express the angiotensin-changing enzyme 2 receptor, making it the vital entry point for the virus, resulting in direct damage. Further analysis suggested that weight problems was connected to compromised immunity within the presence of a hyperinflammatory country. Additionally, a have a look at mentioned that sufferers with metabolic-associated fatty liver disorder exhibited an accelerated susceptibility to Covid-19 contamination. The coronavirus also affected the metabolic repute of sufferers through peroxisome proliferator-activated receptor, highlighting the direct dating among metabolism and irritation.

2.1. Metabolomics

Metabolomics is a way used to degree a big number of metabolites found in bio-fluids, tissues or organisms. Viruses have the capacity to hook up with and use affected person metabolism, making them a top target for reading through metabolomics strategies. Understanding how viruses have an effect on metabolism all through replication and contamination in animals or humans has revealed new insights into capability healing targets. By figuring out viral metabolic pathways, massive antiviral and vaccination techniques can be advanced.

2.2. There are two styles of metabolomics:

- Nontargeted metabolomics is regularly used to compare two biological states. Instead of offering the appropriate awareness of a known metabolite, it serves as a detection device to find out metabolites that fluctuate in reaction to relative awareness changes.
- Targeted metabolomics makes a speciality of quantifying pre-current metabolites in groups with similar chemical structures, consisting of amino acids. This is a greater considerable tool as it often uses stable isotope-labeled metabolites as internal requirements, permitting the amount of selected analyte to be decided by using the ratio of its awareness to that of the labeled degree brought at a recognized awareness.

Metabolomics has provided precious insights into the metabolites related to extraordinary sicknesses, together with those that may predict treatment outcomes and the onset of latest illnesses. For example, in individuals with various types of cardiovascular diseases, targeted metabolomics has revealed an indicator of out of control metabolism of branched-chain amino acids. This discovery changed into made in a examine evaluating obese, insulin-resistant members with lean, insulin-sensitive ones [28]. In addition, several research, which include a cross-sectional examine of people with metabolic syndrome and ranging BMI, have shown a sizable correlation among a cluster of metabolites related to branched-chain amino acids and insulin resistance [29]. This principle changed into also found in Chinese and Asian Indian participants dwelling in Singapore, where their BMI turned into under manage [30]. Furthermore, patients inside the insulin-resistance education atherosclerosis studies on the extremes of insulin sensitivity research confirmed

that the results of mixed aerobic and resistance schooling in insulin-resistant individuals are associated with bcaa metabolites [31]. Both targeted and non-targeted metabolomics research have also shown that bcaa and its metabolites are ability predictors for the onset of type 2 diabetes and obesity, and a few research have shown that metabolomics can be expecting cardiovascular activities.

Table 1 The researches and studies regarding this syndrome year wise and the studies titles with scientist names

Author year	Cohort	findings	Reference
Sampey, 2012	Male Wistar rats	Fat, sodium, and cholesterol in cafeteria diet contribute to MetS.	[32]
Wang, 2011	2422 nondiabetic individuals in Framingham Offspring Study	Metabolism of amino acid participates in the pathogenesis of diabetes.	[33]
Surowiec, 2019	115 Dutch from Leiden Longevity Study	Valeryl carnitine, pyruvic acid, lactic acid, alanine, and diglyceride are connected to MetS.	[34]
Warmbrunn, 2021	132 treatment-naïve males with MetS	Androgen, fatty acid, PE, and PC pathways are the metabolites related to cardiovascular disease.	[35]
Capel, 2020	298 subjects from French MONA LISA trial	Serum BCAA, gamma-glutamyl amino acids, arginine metabolites, and proline levels are changed in MetS.	[36]
Siopi, 2019	23 sedentary males (9 with MetS; 14 controls)	Exercise downregulates BCAA, alanine, acetylcarnitine, choline, and betaine, antagonizing MetS.	[37]
Libert, 2018	90 adults	Worsening health upregulates BCAAs, aromatic amino acids, lysine, and alpha-aminoadipate.	[38]

2.3. Preventions

The important recognition for stopping metabolic syndrome is to encourage healthy lifestyle changes, such as adopting more healthy consuming habits and growing bodily hobby. This can be performed via ingesting extra fruits and greens, increasing fiber consumption, reducing dietary fat, and keeping off excessive-sugar, high-sodium, and processed meals. It is recommended to eat complete culmination as opposed to fruit juice to gain most nutritional blessings. Regular workout also can assist to reduce blood pressure and save you the onset of kind 2 diabetes. Additionally, exercise can enhance emotional properly-being, promote higher sleep, and lower levels of cholesterol. Although life-style changes can considerably lessen the hazard of metabolic syndrome, remedy may additionally nonetheless be important to manipulate blood glucose stages, blood stress, and levels of cholesterol.

2.4. Recent Novel Treatments

In a current take a look at, researchers on the Harrington Discovery Institute at University Hospitals and Case Western Reserve University determined a ability remedy for metabolic syndrome. They discovered a hormone referred to as asprosin, which stimulates appetite and increases blood sugar stages by performing at the hypothalamus and liver. Asprosin stages are elevated in sufferers with metabolic syndrome, main to improved urge for food, weight gain, and insulin resistance. The researchers determined that they might wreck this cycle via blocking off asprosin with monoclonal antibodies.

Metformin, an anti-diabetic drug, can also be used to deal with metabolic syndrome. Another alternative is GLP-1 inhibitors, a category of injectable capsules that assist to decrease blood sugar tiers.

There also are a number of nutraceuticals treatments that may be used to deal with metabolic syndrome. These consist of berberine and bitter melon, which help to modify glucose and lipid metabolism; *Gymnema sylvestre*, which facilitates with obesity; *Irvingia gabonensis*, which facilitates to decrease cholesterol levels; and resveratrol, which has a extensive variety of useful results on metabolic syndrome.

Other novel remedies for metabolic syndrome encompass fecal microbiota transplantation, that can improve gut microbes and insulin sensitivity, and concentrated on stop products of ldl cholesterol.

It is vital to observe that these treatments are still underneath investigation, and extra research is wanted to determine their long-time period effectiveness and safety. However, they provide promising new alternatives for people with metabolic syndrome.

3. Conclusion

As metabolic syndrome is one of the most discussed topics of these days, and there is a myth that this syndrome belongs to the old and well doing societies but in the recent times this myth has been proven wrong as it has been seen in children and lower class also.

There were a lot of treatments and preventions techniques were present and lot of recent developments have also been made recently and further researches are going on like a new hormone named asprosin have been found responsible for appetite and high sugar level in blood. Few nutraceuticals and metabolomics have also been discovered useful for metabolic syndrome.

Physical activities are also been recommended for these kind of health issues but the recent research studies psychological interventions are also very important for these people. So as the metabolic syndrome is of clinically importance and it has enough drawbacks for health to give it enough importance to be included in recent medical researches, and we also have seen a lot of researches are already going on in this field.

Compliance with ethical standards

Acknowledgments

The author thanks Madam Omonova Gavhar Sulstonovna for her support and helping hand in this research and other members of research team.

Disclosure of conflict of interest

The authors declare that there is no conflict of interest regarding this research study.

References

- [1] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001, 285:2486–2497. doi: 10.1001/jama.285.19.2486.
- [2] Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Jr., et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404.
- [3] Alberti K.G., Zimmet P., Shaw J., IDF Epidemiology Task Force Consensus Group The metabolic syndrome—A new worldwide definition. Lancet. 2005, 366:1059–1062. doi: 10.1016/S0140-6736(05)67402-8.
- [4] Hardy D.S., Racette S.B., Garvin J.T., Gebrekristos H.T., Mersha T.B. Ancestry specific associations of a genetic risk score, dietary patterns and metabolic syndrome: A longitudinal ARIC study. BMC Med. Genom. 2021, 14:118. doi: 10.1186/s12920-021-00961-8.
- [5] Zhou J.Y., Song M.Y., Park S. Carbohydrate and sodium intake and physical activity interact with genetic risk scores of four genetic variants mainly related to lipid metabolism to modulate metabolic syndrome risk in Korean middle-aged adults. Br. J. Nutr. 2019, 122:919–927. doi: 10.1017/S0007114519001752.
- [6] Hershey M.S., Sotos-Prieto M., Ruiz-Canela M., Christophi C.A., Moffatt S., Martínez-González M.Á., Kales S.N. The Mediterranean lifestyle (MEDLIFE) index and metabolic syndrome in a non-Mediterranean working population. Clin. Nutr. 2021, 40:2494–2503. doi: 10.1016/j.clnu.2021.03.026.

- [7] Saklayen M.G. The global epidemic of the metabolic syndrome. *Curr. Hypertens Rep.* 2018, 20:12. doi: 10.1007/s11906-018-0812-z.
- [8] Bitew Z.W., Alemu A., Tenaw Z., Alebel A., Worku T., Ayele E.G. Prevalence of metabolic syndrome among children and adolescents in high-income countries: A systematic review and meta-analysis of observational Studies. *BioMed Res. Int.* 2021 doi: 10.1155/2021/6661457.
- [9] Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., Montori V.M. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. *J. Am. Coll. Cardiol.* 2007, 49:403–414. doi: 10.1016/j.jacc.2006.09.032.
- [10] Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P., Rinfret S., Schiffrin E.L., Eisenberg M.J. The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. *J. Am. Coll. Cardiol.* 2010, 56:1113–1132. doi: 10.1016/j.jacc.2010.05.034.
- [11] Zhu S., McClure L.A., Lau H., Romero J.R., White C.L., Babikian V., Nguyen T., Benavente O.R., Kase C.S., Pikula A. Recurrent vascular events in lacunar stroke patients with metabolic syndrome and/or diabetes. *Neurology.* 2015, 85:935–941. doi: 10.1212/WNL.0000000000001933.
- [12] Li X., Li X., Lin H., Fu X., Lin W., Li M., Zeng X., Gao Q. Metabolic syndrome and stroke: A meta-analysis of prospective cohort studies. *J. Clin. Neurosci.* 2017, 40:34–38. doi: 10.1016/j.jocn.2017.01.018.
- [13] Ren H., Wang J., Gao Y., Yang F., Huang W. Metabolic syndrome and liver-related events: A systematic review and meta-analysis. *BMC Endocr. Disord.* 2019, 19:40. doi: 10.1186/s12902-019-0366-3.
- [14] Thomas G., Sehgal A.R., Kashyap S.R., Srinivas T.R., Kirwan J.P., Navaneethan S.D. Metabolic syndrome and kidney disease: A systematic review and meta-analysis. *Clin. J. Am. Soc. Nephrol.* 2011, 6:2364–2373. doi: 10.2215/CJN.02180311.
- [15] Alizadeh S., Ahmadi M., Ghorbani Nejad B., Djazayeri A., Shab-Bidar S. Metabolic syndrome and its components are associated with increased chronic kidney disease risk: Evidence from a meta-analysis on 11109003 participants from 66 studies. *Int. J. Clin. Pract.* 2018, 72:e13201. doi: 10.1111/ijcp.13201.
- [16] Lee M.K., Han K., Kim M.K., Koh E.S., Kim E.S., Nam G.E., Kwon H.S. Changes in metabolic syndrome and its components and the risk of type 2 diabetes: A nationwide cohort study. *Sci. Rep.* 2020, 10:2313. doi: 10.1038/s41598-020-59203-z.
- [17] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002, 106:3143–3421. doi: 10.1161/circ.106.25.3143.
- [18] Aboonabi A., Meyer R.R., Singh I. The association between metabolic syndrome components and the development of atherosclerosis. *J. Hum. Hypertens.* 2019, 33:844–855. doi: 10.1038/s41371-019-0273-0.
- [19] Hess P.L., Al-Khalidi H.R., Friedman D.J., Mulder H., Kucharska-Newton A., Rosamond W.R., Lopes R.D., Gersh B.J., Mark D.B., Curtis L.H. The metabolic syndrome and risk of sudden cardiac death: The atherosclerosis risk in communities study. *J. Am. Heart Assoc.* 2017, 6:e006103. doi: 10.1161/JAHA.117.006103.
- [20] Carnethon M.R., Loria C.M., Hill J.O., Sidney S., Savage P.J., Liu K. Risk factors for the metabolic syndrome. *Diabetes Care.* 2004, 27:2707–2715. doi: 10.2337/diacare.27.11.2707.
- [21] Abbate M., Mascaró C.M., Montemayor S., Casares M., Gómez C., Ugarriza L., Tejada S., Abete I., Zulet M.A., Sureda A., et al. Non-alcoholic fatty liver disease is associated with kidney glomerular hyperfiltration in adults with metabolic syndrome. *J. Clin. Med.* 2021, 10:1717. doi: 10.3390/jcm10081717.
- [22] Önerhag K., Dreja K., Nilsson P.M., Lindgren S. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. *Clin. Res. Hepatol. Gastroenterol.* 2019, 43:542–550. doi: 10.1016/j.clinre.2019.02.004. [
- [23] León-Pedroza J.I., Rodríguez-Cortés O., Flores-Mejía R., Gaona-Aguas C.V., González-Chávez A. Impact of metabolic syndrome in the clinical outcome of disease by SARS-COV-2 in Mexican population. *Arch. Med. Res.* 2021 doi: 10.1016/j.arcmed.2021.04.001.
- [24] Landecho M.F., Marin-Oto M., Recalde-Zamacona B., Bilbao I., Frühbeck G. Obesity as an adipose tissue dysfunction disease and a risk factor for infections—Covid-19 as a case study. *Eur. J. Intern. Med.* 2021 doi: 10.1016/j.ejim.2021.03.031.
- [25] Kuperberg S.J., Navetta-Modrov B. The role of obesity in the immunopathogenesis of COVID-19 respiratory disease and critical illness. *Am. J. Respir. Cell Mol. Biol.* 2021 doi: 10.1165/rcmb.2020-0236TR.
- [26] Marianne Manchester, Anisha Anand, in *Advances in Virus Research*, 2017.

- [27] Christopher B Newgard, Sarah W. Stedman, isotope dilution mass spectrometry, Newgard et al., 2009, Ferrara et al., 2008, Bain et al., 2009 Bain J.R. Stevens R.D. Wenner B.R. Ilkayeva O. Muoio D.M. Newgard C.B. Metabolomics applied to diabetes research: moving from information to knowledge. *Diabetes*. 2009, 58: 2429-244
- [28] Newgard C.B. An J. Bain J.R. Muehlbauer M.J. Stevens R.D. Lien L.F. Haqq A.M. Shah S.H. Arlotto M. Slentz C.A. et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab*. 2009, 9: 311-326.
- [29] Huffman K.M. Shah S.H. Stevens R.D. Bain J.R. Muehlbauer M. Slentz C.A. Tanner C.J. Kuchibhatla M. Houmard J.A. Newgard C.B. Kraus W.E. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. *DiabetesCare*. 2009, 32: 1678-1683
- [30] Tai E.S. Tan M.L. Stevens R.D. Low Y.L. Muehlbauer M.J. Goh D.L. Ilkayeva O.R. Wenner B.R. Bain J.R. Lee J.J. et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. *Diabetologia*. 2010, 53: 757-767
- [31] Palmer N.D. Stevens R.D. Antinozzi P.A. Anderson A. Bergman R.N. Wagenknecht L.E. Newgard C.B. Bowden D.W. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. *J. Clin. Endocrinol. Metab*. 2015, 100: E463-E468. Glynn E.L. Piner L.W. Huffman K.M. Slentz C.A. Elliot-Penry L. AbouAssi H. White P.J. Bain J.R. Muehlbauer M.J. Ilkayeva O.R. et al. Impact of combined resistance and aerobic exercise training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in overweight humans. *Diabetologia*. 2015, 58: 2324-2335
- [32] Sampey B.P., Freerman A.J., Zhang J., Kuan P.F., Galanko J.A., O'Connell T.M., Ilkayeva O.R., Muehlbauer M.J., Stevens R.D., Newgard C.B., et al. Metabolomic profiling reveals mitochondrial-derived lipid biomarkers that drive obesity-associated inflammation. *PLoS ONE*. 2012, 7:e38812. doi: 10.1371/journal.pone.0038812.
- [33] Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P., McCabe E., Lewis G.D., Fox C.S., Jacques P.F., Fernandez C., et al. Metabolite profiles and the risk of developing diabetes. *Nat. Med*. 2011, 17:448-453. doi: 10.1038/nm.2307.
- [34] Surowiec I., Noordam R., Bennett K., Beekman M., Slagboom P.E., Lundstedt T., van Heemst D. Metabolomic and lipidomic assessment of the metabolic syndrome in Dutch middle-aged individuals reveals novel biological signatures separating health and disease. *Metabolomics*. 2019, 15:23. doi: 10.1007/s11306-019-1484-7.
- [35] Warmbrunn M.V., Koopen A.M., de Clercq N.C., de Groot P.F., Kootte R.S., Ter Horst K.W., Hartstra A.V., Serlie M.J., Ackermans M.T., Soeters M.R. Metabolite profile of treatment-naïve metabolic syndrome subjects in relation to cardiovascular disease risk. *Metabolites*. 2021, 11:236. doi: 10.3390/metabo11040236.
- [36] Capel F., Bongard V., Malpuech-Brugère C., Karoly E., Michelotti G.A., Rigaudière J.P., Jouve C., Ferrières J., Marmonier C., Sébédio J.L. Metabolomics reveals plausible interactive effects between dairy product consumption and metabolic syndrome in humans. *Clin. Nutr*. 2020, 39:1497-1509. doi: 10.1016/j.clnu.2019.06.013.
- [37] Siopi A., Deda O., Manou V., Kosmidis I., Komninou D., Raikos N., Theodoridis G.A., Mougios V. Comparison of the serum metabolic fingerprint of different exercise modes in men with and without metabolic syndrome. *Metabolites*. 2019, 9:116. doi: 10.3390/metabo9060116.
- [38] Libert D.M., Nowacki A.S., Natowicz M.R. Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: Amino acid and acylcarnitine levels change along a spectrum of metabolic wellness. *PeerJ*. 2018, 6:e5410. doi: 10.7717/peerj.5410.
- [39] Ila Mishra, Wei Rose Xie, Juan C. Bournat, Yang He, Chunmei Wang, Elizabeth Sabath Silva, Hailan Liu, Zhiqiang Ku, Yinghua Chen, Bernadette O. Erokwu, Peilin Jia, Zhongming Zhao, Zhiqiang An, Chris A. Flask, Yanlin He, Yong Xu, Atul R. Chopra. Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor. *Cell Metabolism*, 2022, 34 (4): 549.
- [40] Ila Mishra, Wei Rose Xie, Juan C. Bournat, Yang He, Chunmei Wang, Elizabeth Sabath Silva, Hailan Liu, Zhiqiang Ku, Yinghua Chen, Bernadette O. Erokwu, Peilin Jia, Zhongming Zhao, Zhiqiang An, Chris A. Flask, Yanlin He, Yong Xu, Atul R. Chopra. Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor. *Cell Metabolism*, 2022, 34 (4): 549.
- [41] Barry McLean MD, PhD. New drug options for Treatment of Metabolic Syndrome.
- [42] Esperanza Martínez-Abundis, Miriam Méndez-Del Villar, Karina G Pérez-Rubio, Laura Y Zuñiga, Marisol Cortez-Navarrete, Alejandra Ramírez-Rodríguez, Manuel González-Ortiz *World J Diabetes* 2016 Apr 10, 7(7):142-52.